Global Drug Discovery Informatics Market Size, Share & Trends Analysis Report By Application (Drug Discovery, and Drug Development), By Function, By End User, By Regional Outlook and Forecast, 2024 - 2031

Global Drug Discovery Informatics Market Size, Share & Trends Analysis Report By Application (Drug Discovery, and Drug Development), By Function, By End User, By Regional Outlook and Forecast, 2024 - 2031

The Global Drug Discovery Informatics Market size is expected to reach $6.5 billion by 2031, rising at a market growth of 10.3% CAGR during the forecast period.

Library and database preparation functions streamline identifying and accessing diverse compound libraries and comprehensive data resources. Thus, the library and database preparation segment would capture around 21.8% revenue share of the market by 2031. These functions enhance the efficiency and effectiveness of drug discovery efforts by providing researchers with the necessary tools and information to identify promising drug candidates and advance them through the drug development pipeline.

The major strategies followed by the market participants are Mergers & Acquisitions as the key developmental strategy to keep pace with the changing demands of end users. For instance, In October 2023, Certara, Inc. acquired Formedix LLC to expand the Certara Pinnacle 21 data standardization platform utilized to prepare and standardize clinical data for analysis and regulatory submissions. Additionally, in February 2023, Accenture PLC took over Bionest to expand its capabilities with Bionest's skilled team as well as to support its clients in bringing therapeutics to patients quickly and more efficiently.

Based on the Analysis presented in the KBV Cardinal matrix; Thermo Fisher Scientific, Inc., Accenture PLC and Oracle Corporation are the forerunners in the market. In August 2023, Thermo Fisher Scientific, Inc. took over CorEvitas, LLC to expand its clinical research business with highly complementary real-world evidence solutions and improve decision-making as well as the time and cost of drug development. Companies such as Agilent Technologies, Inc., Boehringer Ingelheim International GmbH and Infosys Limited are some of the key innovators in the Market.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the market in several ways. The pandemic brought about some negative impacts on the market. One significant challenge was research and clinical trial disruptions due to lockdowns, travel restrictions, and social distancing measures. Many laboratories and research facilities were forced to temporarily close or operate at reduced capacity, leading to delays in data generation, experimentation, and validation of drug candidates. Thus, the pandemic had an overall positive impact on the market.

Market Growth Factors

Big data analytics enable the integration and analysis of vast amounts of biological, chemical, and clinical data from diverse sources, such as genomics, proteomics, metabolomics, and electronic health records. AI algorithms can extract meaningful insights from these datasets, identifying patterns, correlations, and hidden relationships that traditional methods may overlook. Thus, the emergence of big data and artificial intelligence enhances the market.

Additionally, the increasing research and development expenditure in the pharmaceutical industry has led to a growing demand for drug discovery informatics as companies seek more efficient and effective ways to discover new drugs and therapies. Governments worldwide have recognized the importance of R&D in driving innovation in the pharmaceutical sector and have made significant investments to support these efforts. Thus, increasing research and development (R&D) expenditure directly boosts the market.

Market Restraining Factors

Implementing drug discovery informatics platforms and solutions typically requires a substantial initial investment in software licenses, hardware infrastructure, computational resources, and specialized expertise. The upfront costs associated with acquiring and setting up informatics systems can be prohibitive for many pharmaceutical companies, biotech startups, and academic institutions, especially those with limited budgets or resources. Hence, the high cost of implementation presents a significant barrier to entry for many organizations interested in adopting drug discovery informatics solutions.

Application Outlook

Based on application, the market is characterized into drug discovery and drug development. The drug discovery segment garnered 68.5% revenue share in the market in 2023. A key benefit of drug discovery platforms is their ability to analyze vast amounts of data to identify potential drug candidates with high efficacy and safety profiles. As these technologies continue to advance, manufacturers can expect to see even greater innovations in drug discovery and development in the years to come.

Function Outlook

On the basis of function, the market is classified into sequencing & target data analysis, library & database preparation, docking, molecular modeling, and others. In 2023, the docking segment acquired a 11.3% revenue share in the market. Docking optimizes lead compounds identified through virtual screening or experimental assays. It is utilized in drug repurposing efforts to identify existing drugs or compounds with the potential to interact with new targets. Furthermore, docking can also optimize the binding affinity of existing drug candidates.

End User Outlook

By end user, the market is fragmented into biotechnology companies, pharmaceutical companies, contract research organizations, and others. The pharmaceutical companies segment procured 35.7% revenue share in the market in 2023. Pharmaceutical companies’ substantial investments in research and development are directed toward discovering and developing novel therapeutics and acquiring and developing cutting-edge informatics tools and technologies. Additionally, the growing importance of biotechnology in drug discovery and development has expedited the growth of the pharmaceutical sector.

Regional Outlook

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The Europe segment held a 30.5% revenue share in the market in 2023. Europe boasts world-renowned academic and research institutions at the forefront of drug discovery and informatics research. Collaborative initiatives between academia, industry, and government organizations foster innovation and drive advancements in informatics technologies, methodologies, and applications.

Recent Strategies Deployed in the Market

• Apr-2024: Charles River Laboratories International, Inc. formed a collaboration with Deciphex Limited, a software development company focused on digital pathology. Under this collaboration, Charles River Laboratories International, Inc. launched Patholytix Foresight, a non-clinical AI decision support tool developed jointly by Deciphex and Charles River.
• Apr-2024: Certara, Inc. launched Certara Cloud, the unifying platform that integrates its many scientific software solutions. Certara Cloud enhances the customer experience for clients that utilize multiple Certara products. Additionally, it enables Certara to both integrate with and launch interoperable software solutions that span Certara's customers’ workflows from discovery to submission.
• Jan-2024: Thermo Fisher Scientific, Inc. unveiled the Axiom PangenomiX Array, an ethnically diverse array of genetic coverage. The product offers optimal genetic cover for population-scale disease studies and pharmacogenomic research. Additionally, it helps test lots of people for diseases on a large scale, which can greatly improve knowledge about human diseases, making better medicines, understanding how genes affect medicines, and learning about people's ancestry over a long time.
• Dec-2023: Certara, Inc., took over Applied BioMath, LLC, a provider of model-informed drug discovery and development support. Through this acquisition, the companies gain a complementary suite of Applied BioMath, and together they have the scientific and computational expertise to industrialize QSP biosimulation methods.
• Oct-2023: Certara, Inc. acquired Formedix LLC, a provider of clinical metadata repositories and clinical trial automation software. With this acquisition, Formedix expanded the Certara Pinnacle 21 data standardization platform utilized to prepare and standardize clinical data for analysis and regulatory submissions. Moreover, the companies provide a single service that can streamline the flow of clinical data all the way from gathering it to submitting it, making the time it takes to complete studies from setting them up to finalizing reports much quicker.

List of Key Companies Profiled

• Oracle Corporation
• Accenture PLC
• Thermo Fisher Scientific, Inc.
• Boehringer Ingelheim International GmbH
• Infosys Limited
• Charles River Laboratories International, Inc.
• Agilent Technologies, Inc.
• Illumina, Inc.
• Certara, Inc.
• Jubilant Pharmova Limited

Global Drug Discovery Informatics Market Report Segmentation

By Application

• Drug Discovery
• Drug Development

By Function

• Sequencing & Target Data Analysis
• Molecular Modelling
• Library & Database Preparation
• Docking
• Others

By End User

• Pharmaceutical Companies
• Biotechnology Companies
• Contract Research Organizations
• Others

By Geography

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific
• LAMEA
• Brazil
• Argentina
• UAE
• Saudi Arabia
• South Africa
• Nigeria
• Rest of LAMEA